ライフサイエンスコーパス: dopamine D2 receptor

1 and [C-11]raclopride (a radioligand for the dopamine D2 receptor).

2 ntipsychotic drugs were thought to block the dopamine D2 receptor.

3 TM4) as a symmetrical dimer interface in the dopamine D2 receptor.

4 gh stimulation of the 5-HT1A receptor or the dopamine D2 receptor.

5 water-accessible binding-site crevice in the dopamine D2 receptor.

6 o acts at other receptor sites including the dopamine D2 receptor.

7 PS) due to their rapid dissociation from the dopamine D2 receptor.

8 erably Go) over beta-arrestin recruitment at dopamine D2 receptors.

9 ed by SCAM studies of TMH6 in the opioid and dopamine D2 receptors.

10 mate receptors (mGluRs), phospholipase C, or dopamine D2 receptors.

11 ls but also was bidirectionally modulated by dopamine D2 receptors.

12 an embryonic kidney tsA-201 cells along with dopamine D2 receptors.

13 n drug-addicted subjects is a lower level of dopamine D2 receptors.

14 ive blockade of nigrostriatal and mesolimbic dopamine D2 receptors.

15 c effects mainly by acting as antagonists at dopamine D2 receptors.

16 sing pituitary tumor cells stably expressing dopamine D2 receptors.

17 ion tomography and [11C]raclopride to assess dopamine D2 receptors.

18 tly reduced affinity for 5-HT1A, 5-HT2C, and dopamine D2 receptors.

19 ty predominantly through actions at striatal dopamine D2 receptors.

20 localized on the same neurons as Gi-coupled dopamine D2 receptors.

21 f basal ganglia neuronal circuits containing dopamine D2 receptors.

22 quires an optimal dose that blocks the brain dopamine D2 receptors.

23 ite of initial action is through blockade of dopamine D2 receptors.

24 ture-functional selectivity relationships at dopamine D2 receptors.

25 milarities to that effected by activation of dopamine D2 receptors.

26 binding affinities to serotonin 5-HT(2A) and dopamine D2 receptors.

27 imaging assessments and in vitro measures of dopamine D2 receptors.

28 graphy (PET), a radiotracer for the striatal dopamine D2 receptor ([11C]raclopride), and a pharmacolo

29 s ([(3)H]prazosin, IC(50) = 0.54 microM) and dopamine D2 receptors ([(3)H]raclopride, IC(50) = 1.2 mi

30 Chronic blockade of dopamine D2 receptors, a common mechanism of action for

31 ease in cytosolic [Ca2+] ([Ca2+]i) caused by dopamine (D2) receptor activation and the calcium depend

32 nuate cocaine-induced hyperthermia, and that dopamine D2 receptor activation plays a permissive role

33 ng-term depression (eCB-LTD), which requires dopamine D2 receptor activation.

34 Increased striatal dopamine D2 receptor activity is thought to contribute t

35 A/2B receptors versus alpha-1 adrenergic and dopamine D2 receptor affinity.

36 Quinpirole, a dopamine (D2) receptor agonist, reduced [Ca2+]i by 55 +/

37 ing molecules, incorporating ropinirole as a dopamine D2 receptor agonist and ZM 241385 as an adenosi

38 We observed that the dopamine D2 receptor agonist bromocriptine improved the

39 PKC activation by either phorbol ester or a dopamine D2 receptor agonist caused the movement of RACK

40 The dopamine D2 receptor agonist quinpirole, but not the D1

41 on firing by pretreatment with quinpirole, a dopamine D2-receptor agonist, blocked both cocaine- and

42 by administering its precursor l-DOPA and/or dopamine D2-receptor agonists.

43 pparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in t

44 (iii) the transcriptional activation of the dopamine D2 receptor and numerous schizophrenia candidat

45 k of schizophrenia are the gene encoding the dopamine D2 receptor and those involved in the upstream

46 The association between level of dopamine D2 receptors and metabolism in the orbitofronta

47 he major antipsychotic drugs act by blocking dopamine D2 receptors and that dopamine-releasing drugs

48 11C]raclopride to assess the availability of dopamine D2 receptors and with [18F]fluorodeoxyglucose t

49 These results suggest dopamine D2 receptor antagonism holds promise as a poten

50 nist activity (S2 group) or with predominant dopamine D2 receptor antagonist activity (D2 group; HBBM

51 ly, pharmacologic PRL mobilization using the dopamine D2 receptor antagonist domperidone prevented HC

52 halothane anaesthesia) administration of the dopamine D2 receptor antagonist haloperidol, but not rac

53 ment with the typical antipsychotic drug and dopamine D2 receptor antagonist haloperidol.

54 Systemic administration of a selective dopamine D2 receptor antagonist partially blocked the ef

55 Pretreatment with the dopamine D2 receptor antagonist raclopride (1mg/kg, ip)

56 tate, challenging them with the preferential dopamine D2 receptor antagonist raclopride and D1 recept

57 ndicated by their altered sensitivity to the dopamine D2 receptor antagonist raclopride.

58 The dopamine D2 receptor antagonist, raclopride, attenuated

59 or antagonist, SR141716A (5 mg/kg, i.p.), or dopamine D2 receptor antagonist, S(-)-raclopride (5 mg/k

60 ging agent of breast cancer, and (-)-IBZM, a dopamine D2 receptor antagonist.

61 The dopamine D2-receptor antagonist sulpiride decreases spon

62 Dopamine (D2) receptor antagonists were evaluated (Halop

63 results show that the splice variants of the dopamine D2 receptor are differentially distributed and

64 Dopamine D2 receptors are involved with wakefulness, but

65 y transfer to demonstrate that at least four dopamine D2 receptors are located in close molecular pro

66 These results suggest that dopamine D2 receptors are strategically positioned for p

67 were no significant differences in baseline dopamine D2 receptor availability between the Parkinson'

68 Lower levels of dopamine D2 receptor availability have been previously r

69 ood intake, and obese persons have decreased dopamine D2 receptor availability in the striatum.

70 ine release was assessed by the reduction in dopamine D2 receptor availability induced by an acute am

71 s used in 12 rhesus macaques to determine if dopamine D2 receptor availability was associated with th

72 Dopamine D2 receptor availability was measured with [11C

73 Brain dopamine D2 receptor availability was measured with posi

74 Striatal dopamine D2 receptor availability was significantly lowe

75 ated by the amphetamine-induced reduction in dopamine D2 receptor availability, measured as the bindi

76 cerebellum minus 1) was used as a measure of dopamine D2 receptor availability.

77 performance were monitored using a marker of dopamine D2-receptor availability (11)C-raclopride (RAC)

78 otency while reducing alpha-1 adrenergic and dopamine D2 receptor binding affinities substantially, r

79 to assess the relationship between striatal dopamine D2 receptor binding, trinucleotide repeat numbe

80 Dopamine D2 receptor blockade has been an obligate mecha

81 The R isomer did not directly stimulate the dopamine D2 receptor but potentiated the effects of dopa

82 in COS-7 cells or activation of co-expressed dopamine (D2) receptors by quinpirole (100 nM) in oocyte

83 3H]spiroperidol/N-propylnorapomorphine (NPA) dopamine D2 receptor competitive binding assay, 3 and 4,

84 Dopamine D2 receptors contain a cluster of serine residu

85 Overexpression of p11 in dopamine D2 receptor-containing LHb neurons of control m

86 -deficient mice to directly evaluate whether dopamine D2 receptors contribute to alcohol (ethanol) co

87 sly that neural responses to ethanol and the dopamine D2 receptor (D2) agonist 2,10,11-trihydroxy-N-p

88 The dopamine D2 receptor (D2) system has been implicated in

89 ces: fibroblast growth factor (FGF2) and the dopamine D2 receptor (D2).

90 Here we determine the role of dopamine D2 receptors (D2) in PKA signaling responses to

91 Those that express dopamine D2 receptors (D2+) project to the globus pallid

92 lasticity in medium spiny neurons expressing dopamine D2 receptors (D2-MSNs) in the nucleus accumbens

93 n NAc medium spiny neurons (MSNs) expressing dopamine D2 receptors (D2-MSNs), with opposite regulatio

94 d excitation, and physiological responses to dopamine D2-receptor (D2) autoinhibition.

95 Par-4 directly interacts with the dopamine D2 receptor (D2DR) via the calmodulin binding m

96 ve previously described a phenomenon whereby dopamine D2 receptor (D2R) activation elicits afterdepol

97 Aberrant dopamine D2 receptor (D2R) activity is associated with n

98 ines and heteroarylhomopiperazines with high dopamine D2 receptor (D2R) affinity.

99 y 40% increase in membrane expression of the dopamine D2 receptor (D2R) and a twofold increase in D2R

100 te signaling by mu-opioid receptor (MOR) and dopamine D2 receptor (D2R) and are implicated in drug ad

101 ormance, more recent studies have shown that dopamine D2 receptor (D2R) antagonism, paired with a mot

102 ale and female rats received injections of a dopamine D2 receptor (D2R) antagonist (eticlopride), D2R

103 udy, we found that prochlorperazine (PCZ), a dopamine D2 receptor (D2R) antagonist approved to treat

104 eased mu-opioid receptor (MOR) and decreased dopamine D2 receptor (D2R) availability in addictive dis

105 ders are associated with diminished striatal dopamine D2 receptor (D2R) availability, likely reflecti

106 Altered dopamine D2 receptor (D2R) binding in the striatum has b

107 A decrease in dopamine D2 receptor (D2R) binding in the striatum is on

108 mitigates aberrant motor learning induced by dopamine D2 receptor (D2R) blockade in mice.

109 st-in-class beta-arrestin-biased agonists of dopamine D2 receptor (D2R) by extensively exploring mult

110 Evidence indicating an increase in dopamine D2 receptor (D2R) density and occupancy in pati

111 that SB269652 (1) engages one protomer of a dopamine D2 receptor (D2R) dimer in a bitopic mode to al

112 ) adopts a bitopic pose at one protomer of a dopamine D2 receptor (D2R) dimer to negatively modulate

113 ation, with validation in GPCR structure and dopamine D2 receptor (D2R) function.

114 The dopamine D2 receptor (D2R) has received much attention i

115 Adenosine A2A receptor (A2AR)-dopamine D2 receptor (D2R) heteromers are key modulators

116 wed augmented binding of radioligands to the dopamine D2 receptor (D2R) in the striatum as well as ne

117 The dopamine D2 receptor (D2R) is a G protein-coupled recept

118 The dopamine D2 receptor (D2R) is a major component of the d

119 es have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the t

120 Striatal dopamine D2 receptor (D2R) relies upon G protein- and be

121 DA-approved medications target primarily the dopamine D2 receptor (D2R) to inhibit G(i/o)-mediated ad

122 neuromodulator dopamine signals through the dopamine D2 receptor (D2R) to modulate central nervous s

123 selective for the dopamine D3 receptor over dopamine D2 receptor (D2R), despite high sequence identi

124 The dopamine D2 receptor (D2R), like many G-protein-coupled

125 h both the G-protein-coupled receptor (GPCR) dopamine D2 receptor (D2R), regulating its internalizati

126 se hamster ovary cell lines that express the dopamine D2 receptor (D2R), we show here that the D2R ag

127 are highly influenced by cannabinoids and by dopamine D2 receptor (D2R)-mediated regulation of fast-f

128 energic receptor (beta2AR) or the Gi-coupled dopamine D2 receptor (D2R).

129 rapeutic advantages to ligands targeting the dopamine D2 receptor (D2R).

130 gh sequence homology between the D3R and the dopamine D2 receptor (D2R).

131 a) in Tg sera were found to react with human dopamine D2 receptor (D2R).

132 ements for the dopamine D1 receptor (D1R) or dopamine D2 receptor (D2R).

133 s a heteroreceptor complex formation between dopamine D2 receptors (D2R) and NMDA receptor NR2B subun

134 Drugs acting at dopamine D2 receptors (D2R) are commonly used to allevia

135 Dopamine D2 receptors (D2R) are G protein-coupled recept

136 Striatal dopamine D2 receptors (D2R) are major regulators of moto

137 is study, we found that CaMKIIalpha binds to dopamine D2 receptors (D2R) in vitro.

138 Blocking dopamine D2-receptors (D2R) altered generalization behav

139 of the fact that in deep layers of the mPFC, dopamine D2 receptors (D2Rs) are mainly expressed by SC

140 been ascribed to D2Rs.SIGNIFICANCE STATEMENT Dopamine D2 receptors (D2Rs) in the prefrontal cortex (P

141 Dopamine D2 receptors (D2Rs) play a major role in the fu

142 Presynaptic dopamine D2 receptors (D2Rs) regulate dopamine transport

143 Dopamine D2 receptors (D2Rs) suppress lateral inhibition

144 Striatal dopamine D2 receptors (D2Rs) were downregulated in obese

145 ng lactotroph cells by activating lactotroph dopamine D2 receptors (D2Rs).

146 l ganglia of adult mice that is regulated by dopamine D2 receptors (D2Rs).

147 enes implicated in impulsivity, encoding the dopamine D2 receptor (DA D2R) and the 5-HT2c receptor (5

148 oral responses previously found to relate to dopamine D2 receptor density (responsivity to tactile st

149 olinska Scales of Personality are related to dopamine D2 receptor density and extends this finding by

150 tal retardation homologue FXR1 and regulates dopamine D2 receptor density.

151 er the frontal cortex of awaken mice induces dopamine D2 receptor dependent persistent changes of CDK

152 This is associated with dopamine D2 receptor-dependent increased striatal protei

153 escence also increased the expression of the dopamine D2 receptor, dopamine transporter, and adenosin

154 red food reinforcement, polymorphisms of the dopamine D2 receptor (DRD2) and dopamine transporter (DA

155 e D1 receptor (DRD1) antagonist SCH 23390 or dopamine D2 receptor (DRD2) antagonist sulpiride into th

156 ength polymorphism, which is associated with dopamine D2 receptor (DRD2) gene binding in the striatum

157 on of DTNBP1 siRNA on cell surface levels of dopamine D2 receptor (DRD2) in human SH-SY5Y neuroblasto

158 ted the sensitivity of the microPET to image dopamine D2 receptor (DRD2) KO mice (D2-/-).

159 Subcortical dopamine D2 receptor (DRD2) signaling is implicated in c

160 These dopamine D2 receptor-enriched modules may play an import

161 ve symptoms of schizophrenia by antagonizing dopamine D2 receptors expressed by striatal spiny projec

162 hat was induced by activation of recombinant dopamine D2 receptors expressed in C6 glioma and human e

163 II of the PrL, p11 is highly concentrated in dopamine D2 receptor-expressing (D2(+)) glutamatergic ne

164 a balanced loss of NMDARs from both D1R and dopamine D2 receptor-expressing (D2R) MSNs is permissive

165 ic nicotine (cNIC) on synaptic plasticity in dopamine D2 receptor-expressing medium-spiny neurons in

166 itored population-level Ca(2+) activities of dopamine D2-receptor-expressing medium spiny neurons (D2

167 ens (NAcc) as well as MSN-D2 (MSN-expressing dopamine D2 receptors) from the shell of NAcc.

168 Pharmacological manipulation of dopamine D2 receptor function with quinpirole (agonist)

169 oduction of the R1441C mutation also impairs dopamine D2 receptor function, as suggested by decreased

170 e present results provide a key link between dopamine D2 receptor function, impulsivity, and frontost

171 e highly enriched in striatum, in modulating dopamine D2 receptor function.

172 The human dopamine D2 receptor gene (DRD2) has three polymorphic v

173 Absence of the murine dopamine D2 receptor gene (drd2) produces bradykinesia a

174 A SNP (rs17601612) in the dopamine D2 receptor gene (DRD2) was significantly assoc

175 lymorphisms, rs2283265 and rs1076560, in the dopamine D2 receptor gene (DRD2) were found to be signif

176 viates the transcriptional inhibition of the dopamine D2 receptor gene by mutant htt.

177 verses the transcriptional inhibition of the dopamine D2 receptor gene caused by mutant huntingtin, a

178 The dopamine D2 receptor has two splice variants, D2S (Short

179 We show that blockade of dopamine D2 receptors has profound effects on the functi

180 reatly reduced FAA, whereas mice lacking the dopamine D2 receptor have normal FAA.

181 express a signaling-deficient form of human dopamine D2 receptor (hD2R).

182 ant DNA technique to investigate the role of dopamine D2 receptor in rhinal cortex for this type of l

183 Opioid stimulation of JNK also inactivates dopamine D2 receptors in a PRDX6-dependent manner.

184 ine activity we measured the availability of dopamine D2 receptors in brain.

185 The authors have shown that decreases in dopamine D2 receptors in cocaine abusers were associated

186 sing increased the amount or availability of dopamine D2 receptors in dominant monkeys and produced n

187 Here, we demonstrate that overexpression of dopamine D2 receptors in medium spiny neurons increases

188 re to identify a surrogate biomarker for the Dopamine D2 receptors in the brain by comparing patients

189 After demonstrating dopamine D2 receptors in the glomerular and olfactory ne

190 Our results indicate that quinpirole acts at dopamine D2 receptors in the nucleus accumbens to inhibi

191 We found that blocking dopamine D2 receptors in the retina during the day mimic

192 are glutamatergic and regulated primarily by dopamine D2 receptors in the striatum.

193 study was undertaken to examine the role of dopamine D2-receptors in the regulation of neurotensin r

194 We report that dopamine-D2 receptors induce PKA Calpha translocation an

195 expression greatly accelerated the decay of dopamine D2 receptor-induced GIRK current.

196 Dopamine D2 receptor interactions with arrestins and arr

197 Signaling through the dopamine D2 receptor is critical for all of these proces

198 Activation of dopamine D2 receptors is known to potently modulate stri

199 f the radioligand 11C-labelled raclopride to dopamine D2 receptors is sensitive to levels of endogeno

200 n the third membrane-spanning segment of the dopamine D2 receptor, is exposed in the binding-site cre

201 Stress and dopamine D2 receptor levels (DRD2) have been shown to pl

202 Although ventral prefrontal dopamine D2 receptor levels predict "perseverative" erro

203 This study assessed whether brain dopamine D2 receptor levels, which show significant inte

204 The binding site of the dopamine D2 receptor, like that of homologous G-protein-

205 The binding site of the dopamine D2 receptor, like that of homologous G-protein-

206 The binding-site of the dopamine D2 receptor, like that of other homologous G pr

207 The binding site of the dopamine D2 receptor, like that of other homologous G pr

208 The binding site of the dopamine D2 receptor, like that of other homologous G-pr

209 methods to study genetic linkage between the dopamine D2 receptor locus and alcoholism.

210 adenylyl cyclase activity while suppressing dopamine D2 receptor-mediated inhibition.

211 These data demonstrate that basal ganglia dopamine D2 receptor-mediated neurotransmission is invol

212 ryonic kidney 293 cells completely abolished dopamine D2 receptor-mediated potentiation of AC2 activi

213 This was accomplished by examining the dopamine D2 receptor-mediated synaptic current that resu

214 ing offspring did not experience the loss of dopamine D2 receptor mRNA characteristic of HD mice, and

215 gical investigations of bivalent ligands for dopamine D2 receptor/neurotensin NTS1 receptor (D2R/NTS1

216 ride positron emission tomography to measure dopamine D2 receptor occupancy by the endogenous transmi

217 counter-therapeutic functional adaptation to dopamine D2 receptor occupancy required for medication e

218 irst direct evidence for the localization of dopamine D2 receptors on striatal cholinergic interneuro

219 eceptor mechanisms: (1) direct inhibition by dopamine D2 receptors on the cholinergic neurons, and (2

220 e have mapped the homodimer interface in the dopamine D2 receptor over the entire length of the fourt

221 Aripiprazole is a dopamine D2 receptor partial agonist with partial agonis

222 Antagonism of GABA(B) receptors or dopamine D2 receptors partially reversed the reduction i

223 Dopamine D2 receptor-promoted activation of Galpha(o) ov

224 Bromocriptine, acting through the dopamine D2 receptor, provides robust protection against

225 (WT, C57BL/6J) animals were imaged with the dopamine D2 receptor radioligand (11)C-raclopride, the P

226 (WT, C57BL/6J) animals were imaged with the dopamine D2 receptor radioligand (11)C-raclopride, the P

227 ron emission tomography and [11C]raclopride (dopamine D2 receptor radioligand sensitive to competitio

228 erwent positron emission tomography with the dopamine D2 receptor radiotracer carbon 11-labeled FLB45

229 ose with substance abuse disorders may share dopamine D2 receptor-related vulnerabilities, and opposi

230 Here, we report that the dopamine D2 receptor selectively modulates the neural ac

231 conditional transgenic mouse overexpressing dopamine D2 receptors selectively in the striatum.

232 hysiological studies identified a deficit in dopamine D2 receptor signaling in the BLA of Lmo4-defici

233 tor complex and is involved in mu-opiate and dopamine D2 receptor signaling, both of which are though

234 lity trait involving personal detachment and dopamine D2 receptor specific binding in healthy subject

235 Atypical melanotrophs remain competent for dopamine D2 receptor stimulation and undergo S-phase apo

236 tribution of a recently cloned member of the dopamine D2 receptor subfamily, the D3 receptor, has led

237 red including dopamine transporter (DAT) and dopamine D2 receptor subtype (D2r) ligand levels as well

238 ur-residue segment (residues 212-215) of the dopamine D2 receptor that is necessary for arrestin bind

239 In MSNs presumably expressing dopamine D2 receptors, tLTP, the main form of plasticity

240 agonist N-propylnorapomorphine (NPA) to the dopamine D2 receptor was also examined.

241 A homology model of the dopamine D2 receptor was constructed based on the crysta

242 The availability of dopamine D2 receptor was decreased in obese individuals

243 ools for the highly therapeutically relevant dopamine D2 receptor, we synthesized a collection of ago

244 Using light microscopy, dopamine D2 receptors were localized on the cell somata

245 The dopamine D2 receptor, which attenuates acetylcholine rel

246 ssing a wild-type G alpha(i) subunit and the dopamine D2 receptor with the agonist ligand nor-apomorp

247 Reduction of dopamine signaling through the dopamine D2 receptor with the use of gene knockouts in C